Evidence map›Paper›PMID 37460535›Full record

ArticleCell discovery2023

In vivo treatment of tyrosinaemia with hypercompact Cas12f1.

Ruochen Guo, Zhifang Li, Guoling Li, Hainan Zhang, Chang Zhang, Xiaona Huo, Xiaoyin Zhang, Xiali Yang, Rongrong Yang, Yuanhua Liu and 5 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell discovery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Recent application of CRISPR-Cas12 and OMEGA system for genome editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ruochen Guo *Lingang Laboratory, Shanghai, China.
Zhifang Li *Lingang Laboratory, Shanghai, China.
Guoling Li *Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Hainan Zhang *HuidaGene Therapeutics Inc, Shanghai, China.
Chang Zhang *Institute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Xiaona HuoLingang Laboratory, Shanghai, China.
Xiaoyin ZhangLingang Laboratory, Shanghai, China.
Xiali YangInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Rongrong YangLingang Laboratory, Shanghai, China.
Yuanhua LiuInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Xiaozhi SunLingang Laboratory, Shanghai, China.
Xinyu LiuInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Hui YangInstitute of Neuroscience, State Key Laboratory of Neuroscience, Key Laboratory of Primate Neurobiology, CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. huiyang@huidagene.com.ORCID http://orcid.org/0000-0002-8023-0230
Yingsi ZhouHuidaGene Therapeutics Inc, Shanghai, China. yingsizhou@huidagene.com.
Chunlong XuLingang Laboratory, Shanghai, China. xucl@lglab.ac.cn.ORCID http://orcid.org/0000-0003-3533-3465

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37460535
PMCPMC10352374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.